Highlights Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Real-time Estimate Cboe BZX Other stock markets 17:15:23 14/05/2024 BST			5-day change	1st Jan Change
3.705 ^USD	+4.66%		+7.18%	+594.60%

01:59pm	Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target	MT
05-02	Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-06	CI
Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan	02-22	CI
Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021	01-05	CI
Elevation Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021	16/08/23	CI
Elevation Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China	05/06/23	CI
Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Elevation Oncology, Inc. Presents EO-3021 Preclinical Proof-Of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023	17/04/23	CI
Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/03/23	CI
ELEVATION ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	09/03/23	AQ
Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/03/23	CI
Elevation Oncology, Inc. Announces Plans to Prioritize Key Research and Development Efforts to Advance EO-3021	06/01/23	CI
ELEVATION ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	03/11/22	AQ
Elevation Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI
Elevation Oncology, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2022	04/08/22	CI
ELEVATION ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	04/08/22	AQ
Elevation Oncology, Inc. Enters License Agreement with CSPC Megalith Biopharmaceutical Co., Ltd	28/07/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Highlights

Filters